ESMO E-Learning: Multidisciplinary Treatment for Glioblastoma

Learning Objectives

  • To provide an update on key diagnostic, clinical, molecular, prognostic and predictive characteristics in patients with newly diagnosed and recurrent glioblastoma
  • To describe best practices and current treatment recommendations
  • To provide an update on recent clinical trials and ongoing research seeking to improve treatment outcomes
Title Duration Content CME Points CME Test
Multidisciplinary Treatment for Glioblastoma 20 min. 25 slides 1 Take Test
Matthias Preusser
Matthias Preusser
Read more

Glioblastoma is the most common primary brain tumour in adult patients. It is a cancer type characterised with a high morbidity and mortality, with a median overall survival of 14 to 17 months. This E-learning module is part of ESMO effort to provide an update on standard treatment recommendations and raise interest among a new generation of oncologists towards a type of disease in which research is a key factor towards improved outcomes.

Most patients develop de novo tumours with a short clinical history of days to a few months (primary glioblastoma) and less than 10% of tumours develop from lower grade gliomas (secondary glioblastomas), typically with a clinical history of years. The clinical presentation is highly variable and it depends on tumour localisation and size.

Standard first-line therapy consists of maximal safe resection and combined radiochemotherapy with temozolomide. Currently there is no accepted treatment standard for recurrent glioblastoma. Supportive treatment with anti-oedema and anticonvulsive therapy is of particular importance in most patients. Ongoing trials evaluate novel strategies for newly diagnosed glioblastoma and patients with recurrent glioblastoma.  

In this E-learning module, the author covers in a very educational manner: 

  • epidemiology of glioblastoma,
  • relative frequencies of gliomas,
  • risk factors,
  • clinical presentation,
  • neuroimaging features,
  • histopathology features,
  • molecular pathology,
  • prognostic factors,
  • standard treatment strategies in newly diagnosed and patients with recurrent glioblastoma,
  • current therapy schedule and key recommendations based on randomised phase III trials,
  • treatment specificities in elderly patients,
  • standards in anti-oedema and anticonvulsive therapies, as well as a summary on currently ongoing research strategies
Last update: 05 August 2015

The author has reported to have received grants from Roche, GSK, Boehringer-Ingelheim, MSD and honoraria from GSK, Roche and BMS